Related Experiment Video
Updated: Aug 16, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
Potent inhibition of human telomerase by helenalin
Pei-Rong Huang1, Yuan-Ming Yeh, Tzu-Chien V Wang
1Department of Molecular and Cellular Biology, Chang Gung University, Kwei-San, Tao-Yuan 333, Taiwan, ROC.
Abstract:
Telomerase activity is repressed in normal human somatic cells, but is activated in most cancers, suggesting that telomerase may be an important target for cancer therapy. Inhibition of telomerase in cancer cells has been shown to limit the growth of human cancer cells in culture. In this study, we report that helenalin, a natural sesquiterpene lactone, is a potent and selective inhibitor for human telomerase. In vitro studies indicate that this drug can inactivate telomerase directly in a manner that is dependent on concentration and time. The inhibitory action of this drug on telomerase is selective since the presence of excessive externally added proteins did not protect the inhibition and all of the other enzymes tested in this study were not inhibited by this drug. Furthermore, we demonstrated that helenalin can inhibit the expression of hTERT and telomerase in hematopoietic cancer cells. Therefore, the anti-tumor activity of helenalin is attributed, at least in part, to the inhibition of telomerase.
Insights
Helenalin, a natural compound, effectively inhibits human telomerase, a key target in cancer therapy. This selective inhibition of telomerase and hTERT expression in cancer cells contributes to helenalin's anti-tumor activity.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Telomerase is active in most cancers but repressed in normal cells, making it a significant cancer therapy target.
- Inhibiting telomerase has shown potential in limiting cancer cell growth in vitro.
- Helenalin is a natural sesquiterpene lactone with potential therapeutic applications.
Purpose of the Study:
- To investigate helenalin as a potent and selective inhibitor of human telomerase.
- To elucidate the mechanism of helenalin's action on telomerase.
- To determine the role of telomerase inhibition in helenalin's anti-tumor effects.
Main Methods:
- In vitro studies to assess telomerase inhibition by helenalin.
- Time- and concentration-dependent inactivation assays.
- Selectivity tests against other enzymes and protein effects.
- Analysis of hTERT and telomerase expression in hematopoietic cancer cells.
Main Results:
- Helenalin directly inactivates human telomerase in a dose- and time-dependent manner.
- Helenalin exhibits selectivity, with no inhibition of other tested enzymes and resistance to protein interference.
- Helenalin significantly inhibits hTERT and telomerase expression in hematopoietic cancer cells.
Conclusions:
- Helenalin is a potent and selective inhibitor of human telomerase.
- The anti-tumor activity of helenalin is, at least partly, due to its telomerase inhibitory effects.
- Helenalin represents a promising therapeutic agent targeting telomerase in cancer treatment.
Related Concept Videos
Telomeres and Telomerase
Replicative Cell Senescence
Replication in Eukaryotes
Many Proteins Orchestrate Replication at the Origin
Eukaryotic replication follows many of the same...
Replication in Eukaryotes
Drugs that Stabilize Microtubules

